Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) shares fell 2.9% during mid-day trading on Tuesday after HC Wainwright lowered their price target on the stock from $18.00 to $16.00. HC Wainwright currently has a buy rating on the stock. Astria Therapeutics traded as low as $9.51 and last traded at $9.52. 312,375 shares were traded during mid-day trading, a decline of 68% from the average session volume of 972,972 shares. The stock had previously closed at $9.80.
Other equities research analysts have also issued research reports about the company. Wedbush reiterated an “outperform” rating and issued a $17.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 26th. Jefferies Financial Group upped their price target on Astria Therapeutics from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, March 25th.
Insider Buying and Selling
In other news, Director Perceptive Advisors Llc purchased 2,481,350 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were acquired at an average cost of $12.09 per share, with a total value of $29,999,521.50. Following the purchase, the director now owns 4,873,721 shares in the company, valued at $58,923,286.89. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Christopher Morabito sold 9,200 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $11.15, for a total value of $102,580.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Perceptive Advisors Llc bought 2,481,350 shares of Astria Therapeutics stock in a transaction dated Thursday, February 1st. The stock was acquired at an average cost of $12.09 per share, with a total value of $29,999,521.50. Following the completion of the acquisition, the director now owns 4,873,721 shares of the company’s stock, valued at $58,923,286.89. The disclosure for this purchase can be found here. 3.40% of the stock is owned by company insiders.
Hedge Funds Weigh In On Astria Therapeutics
Several institutional investors have recently modified their holdings of the business. AJOVista LLC bought a new position in shares of Astria Therapeutics in the fourth quarter valued at approximately $51,000. Jump Financial LLC bought a new position in shares of Astria Therapeutics in the third quarter valued at approximately $111,000. Panagora Asset Management Inc. bought a new position in shares of Astria Therapeutics in the fourth quarter valued at approximately $119,000. Trexquant Investment LP bought a new position in Astria Therapeutics during the fourth quarter valued at $409,000. Finally, ADAR1 Capital Management LLC bought a new position in Astria Therapeutics during the fourth quarter valued at $1,469,000. 98.98% of the stock is owned by institutional investors.
Astria Therapeutics Price Performance
The firm has a fifty day simple moving average of $13.31 and a two-hundred day simple moving average of $9.27. The firm has a market capitalization of $529.24 million, a P/E ratio of -4.12 and a beta of 0.69.
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last announced its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, research analysts anticipate that Astria Therapeutics, Inc. will post -1.55 EPS for the current year.
About Astria Therapeutics
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.